1. Key messages Stephen S Lim, et al. Lancet 2007; 370: 2054-62

2. Countries that account for 80% of global chronic disease deaths in low-income and middle-income countries Stephen S Lim, et al. Lancet 2007; 370: 2054-62

3. Main model parameters Stephen S Lim, et al. Lancet 2007; 370: 2054-62

4. Example of an absolute risk chart using age, sex, smoking status, systolic blood pressure, and body-mass index *Numbers are 10-year risk of fatal ischaemic heart disease or cardiovascular events in Mexico Stephen S Lim, et al. Lancet 2007; 370: 2054-62

5. Patterns of scale-up of a multidrug regimen for patients at high risk of cardiovascular disease by Commission on Macroeconomics in Health (CMH) category, expressed as a proportion of those accessing health services Stephen S Lim, et al. Lancet 2007; 370: 2054-62

6. Effects of diff erent individual drugs, measured as relative risk, on fatal and non-fatal ischaemic heart disease and cerebrovascular disease Stephen S Lim, et al. Lancet 2007; 370: 2054-62

7. Patient cost parameters Stephen S Lim, et al. Lancet 2007; 370: 2054-62

8. Cumulative thousands of deaths averted with a multidrug regimen for the prevention of cardiovascular disease by sex, 2006-15 Stephen S Lim, et al. Lancet 2007; 370: 2054-62

9. Person-years of treatment and number of deaths averted by age and sex, 2006-15 Stephen S Lim, et al. Lancet 2007; 370: 2054-62

10. Cumulative financial cost of scaling up a multidrug regimen for the prevention of cardiovascular disease, 2006-15 Stephen S Lim, et al. Lancet 2007; 370: 2054-62

11. Average yearly cost (US$ per head) of scaling up a multidrug regimen for the prevention of cardiovascular disease by country, 2006-15 Stephen S Lim, et al. Lancet 2007; 370: 2054-62

12. Average yearly cost (proportion of current health expenditure) of scaling up a multidrug regimen for the prevention of cardiovascular disease by country, 2006-15 Stephen S Lim, et al. Lancet 2007; 370: 2054-62